SG11201408051VA - Cho expression system - Google Patents

Cho expression system

Info

Publication number
SG11201408051VA
SG11201408051VA SG11201408051VA SG11201408051VA SG11201408051VA SG 11201408051V A SG11201408051V A SG 11201408051VA SG 11201408051V A SG11201408051V A SG 11201408051VA SG 11201408051V A SG11201408051V A SG 11201408051VA SG 11201408051V A SG11201408051V A SG 11201408051VA
Authority
SG
Singapore
Prior art keywords
international
boetie
sanofi
rue
paris
Prior art date
Application number
SG11201408051VA
Other languages
English (en)
Inventor
Catherine Devaud
Bruno Dumas
Nabil Lounis
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201408051VA publication Critical patent/SG11201408051VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00Vectors comprising a special origin of replication system
    • C12N2820/55Vectors comprising a special origin of replication system from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002Glutamate-ammonia ligase (6.3.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201408051VA 2012-06-14 2013-06-14 Cho expression system SG11201408051VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305677.2A EP2674495A1 (en) 2012-06-14 2012-06-14 CHO expression system
PCT/EP2013/062400 WO2013186371A1 (en) 2012-06-14 2013-06-14 Cho expression system

Publications (1)

Publication Number Publication Date
SG11201408051VA true SG11201408051VA (en) 2015-01-29

Family

ID=48700539

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408051VA SG11201408051VA (en) 2012-06-14 2013-06-14 Cho expression system

Country Status (15)

Country Link
US (1) US9334489B2 (enrdf_load_html_response)
EP (2) EP2674495A1 (enrdf_load_html_response)
CN (2) CN104540950A (enrdf_load_html_response)
AR (1) AR091418A1 (enrdf_load_html_response)
AU (1) AU2013276467B2 (enrdf_load_html_response)
CA (1) CA2876550C (enrdf_load_html_response)
DK (1) DK2861741T3 (enrdf_load_html_response)
ES (1) ES2627954T3 (enrdf_load_html_response)
HU (1) HUE032968T2 (enrdf_load_html_response)
IN (1) IN2014KN02823A (enrdf_load_html_response)
MX (1) MX353499B (enrdf_load_html_response)
SG (1) SG11201408051VA (enrdf_load_html_response)
TW (1) TWI605123B (enrdf_load_html_response)
UY (1) UY34860A (enrdf_load_html_response)
WO (1) WO2013186371A1 (enrdf_load_html_response)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
US10557125B2 (en) 2014-10-23 2020-02-11 Sanofi Selection marker for cell transfection and protein production
EP3408397B1 (en) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
JP2020501506A (ja) 2016-09-07 2020-01-23 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. 抗NKp46抗体およびその治療的使用
KR20200018488A (ko) 2017-05-24 2020-02-19 토리스 게엠베하 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
CN108085337B (zh) * 2017-12-28 2020-10-16 未名生物医药有限公司 一种gs表达系统细胞株的筛选方法
CN109988777A (zh) * 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
CA3140765A1 (en) * 2019-06-07 2020-12-10 Biocon Biologics Limited Mammalian expression vectors
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
TW202227622A (zh) 2020-09-21 2022-07-16 法商賽諾菲公司 用於生產治療蛋白之高生產重組中國倉鼠卵巢細胞株之世代
EP4384623A1 (en) * 2021-08-03 2024-06-19 Shanghai Zhenge Biotechnology Co., Ltd. Selectable markers for eukaryotic expression system
CN118804978A (zh) * 2021-12-27 2024-10-18 上海臻格生物技术有限公司 用于重组生产系统的新型标志物
CN115287300A (zh) * 2022-08-11 2022-11-04 无锡多宁生物科技有限公司 一种增强ExpiCHO细胞瞬时转染抗体表达的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8924021D0 (en) * 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
KR100267720B1 (ko) * 1997-12-29 2001-03-02 박호군 사람 글루타민 합성효소 유전자를 포함하는 발현벡터 및 이를 이용하여 동물세포에서 에리트로포이에틴을 고수율로 생산하는 방법
GB0216648D0 (en) * 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2004229501B2 (en) * 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
CN101875957A (zh) * 2004-12-30 2010-11-03 新加坡科技研究局 中国仓鼠凋亡相关基因
GB0508154D0 (en) * 2005-04-22 2005-06-01 Lonza Biologics Plc Mammalian expression vector comprising the mCMV promoter and first intron of hCMV major immediate early gene
GB0510277D0 (en) * 2005-05-20 2005-06-29 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
JP2010515435A (ja) * 2007-01-08 2010-05-13 ミリポア・コーポレイション 遺伝子増幅を不要とする高発現細胞株
AU2008309934B2 (en) * 2007-10-12 2014-03-06 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
EA201000809A1 (ru) 2007-11-16 2010-12-30 Те Рокфеллер Юниверсити АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА

Also Published As

Publication number Publication date
EP2861741A1 (en) 2015-04-22
CN104540950A (zh) 2015-04-22
MX2014015280A (es) 2015-06-23
EP2861741B1 (en) 2017-04-12
TWI605123B (zh) 2017-11-11
CA2876550A1 (en) 2013-12-19
ES2627954T3 (es) 2017-08-01
AR091418A1 (es) 2015-02-04
US9334489B2 (en) 2016-05-10
MX353499B (es) 2018-01-16
CN107881151A (zh) 2018-04-06
TW201402817A (zh) 2014-01-16
EP2674495A1 (en) 2013-12-18
UY34860A (es) 2014-01-31
DK2861741T3 (en) 2017-07-17
WO2013186371A1 (en) 2013-12-19
AU2013276467A1 (en) 2015-01-15
IN2014KN02823A (enrdf_load_html_response) 2015-05-08
AU2013276467B2 (en) 2018-08-30
CA2876550C (en) 2021-07-13
HUE032968T2 (en) 2017-11-28
US20150140607A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
SG11201408051VA (en) Cho expression system
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909777YA (en) Modulatory polynucleotides
SG11201807912SA (en) Vaccine against rsv
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201407370QA (en) Humanized il-7 rodents
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201407472SA (en) Motion compensation and motion estimation leveraging a continuous coordinate system
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201803642WA (en) Bacteria-based protein delivery
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407898WA (en) Electrode testing apparatus
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201407860PA (en) Exendin-4 peptide analogues